These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 10607253)

  • 41. Predictive value of early HCV RNA quantitation for sustained response in nonresponders receiving daily interferon and ribavirin therapy.
    Trimoulet P; de Lédinghen V; Foucher J; Castéra L; Fleury H; Couzigou P
    J Med Virol; 2004 Jan; 72(1):46-51. PubMed ID: 14635010
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Permanent response to alpha-interferon therapy in chronic hepatitis C is preceded by rapid clearance of HCV-RNA from serum.
    Ampurdanés S; Olmedo E; Maluenda MD; Forns X; López-Labrador FX; Costa J; Sánchez-Tapias JM; de Anta MT; Rodés J
    J Hepatol; 1996 Dec; 25(6):827-32. PubMed ID: 9007709
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hepatitis C virus (HCV) RNA level determined by second-generation branched-DNA probe assay as predictor of response to interferon treatment in patients with chronic HCV viremia.
    Furusyo N; Hayashi J; Kashiwagi K; Nakashima H; Nabeshima S; Sawayama Y; Kinukawa N; Kashiwagi S
    Dig Dis Sci; 2002 Mar; 47(3):535-42. PubMed ID: 11911338
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy.
    Myers RP; Benhamou Y; Bochet M; Thibault V; Mehri D; Poynard T
    AIDS; 2004 Jan; 18(1):75-9. PubMed ID: 15090832
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Usefulness of viral kinetics for early prediction of a sustained virological response in HCV-1 non-responders re-treated with pegylated interferon and ribavirin.
    Deltenre P; Corouge M; Canva V; Castel H; Wartel F; Dharancy S; Louvet A; Lazrek M; Moreno C; Henrion J; Mathurin P
    J Hepatol; 2011 Nov; 55(5):989-95. PubMed ID: 21354445
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment.
    Campistol JM; Esforzado N; Martínez J; Roselló L; Veciana L; Modol J; Casellas J; Pons M; de Las Cuevas X; Piera J; Oliva JA; Costa J; Barrera JM; Bruguera M
    Nephrol Dial Transplant; 1999 Nov; 14(11):2704-9. PubMed ID: 10534516
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
    Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
    Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intrahepatic mRNA levels of interferon gamma and tumor necrosis factor alpha and response to antiviral treatment of chronic hepatitis C.
    Dumoulin FL; Wennrich U; Nischalke HD; Leifeld L; Fischer HP; Sauerbruch T; Spengler U
    J Hum Virol; 2001; 4(4):195-9. PubMed ID: 11694847
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Transient reappearance of serum hepatitis C virus RNA observed by real-time PCR during antiviral therapy with peginterferon and ribavirin in patients with HCV genotype 1b.
    Toyoda H; Kumada T; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Tada T; Takagi M; Hiramatsu T; Hosokawa T; Arakawa T; Fujimori M
    J Clin Virol; 2010 Mar; 47(3):258-62. PubMed ID: 20116330
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Early changes in hepatitis C virus (HCV) RNA levels predict response to interferon treatment in noncirrhotic HCV patients.
    Fallows G; Kaita K; Minuk G; Penner F; Smart G; Dawood M; Rosser B
    Can J Gastroenterol; 2000; 14 Suppl B():30B-35B. PubMed ID: 10938502
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Optimal follow-up time to determine the sustained virological response in patients with chronic hepatitis C receiving pegylated-interferon and ribavirin.
    Namikawa M; Kakizaki S; Yata Y; Yamazaki Y; Horiguchi N; Sato K; Takagi H; Mori M
    J Gastroenterol Hepatol; 2012 Jan; 27(1):69-75. PubMed ID: 21649727
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term responders without eradication of hepatitis C virus after interferon therapy: characterization of clinical profiles and incidence of hepatocellular carcinoma.
    Yabuuchi I; Imai Y; Kawata S; Tamura S; Noda S; Inada M; Maeda Y; Shirai Y; Fukuzaki T; Kaji I; Ishikawa H; Matsuda Y; Nishikawa M; Seki K; Matsuzawa Y
    Liver; 2000 Jul; 20(4):290-5. PubMed ID: 10959807
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Relationship between biochemical and virological responses to interferon therapy in chronic hepatitis C infection. Consensus Interferon Study Group.
    Pockros PJ; Tong M; Lee WM; van Leeuwen DJ; Keeffe EB; Bala K; Killenberg PG; Foust RT; Rosenblate HJ; Payne KM; Fromm H; Lesesne HR; Black M
    J Viral Hepat; 1998 Jul; 5(4):271-6. PubMed ID: 9751014
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hepatitis C Viral Kinetic Changes in a Retrospective Cohort Study of Chronic Hepatitis C Virus Egyptian Patients on Pegylated Interferon and Ribavirin Therapy.
    Esmat GE; Al Akel W; Abdel Aziz RA; Al Sayed Taha A; Sabry D; Rashed LA; Mostafa A; El Kazaz AY; Ahmed SH
    J Interferon Cytokine Res; 2016 Mar; 36(3):149-58. PubMed ID: 26982165
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impaired response to alpha interferon in patients with an inapparent hepatitis B and hepatitis C virus coinfection.
    Zignego AL; Fontana R; Puliti S; Barbagli S; Monti M; Careccia G; Giannelli F; Giannini C; Buzzelli G; Brunetto MR; Bonino F; Gentilini P
    Arch Virol; 1997; 142(3):535-44. PubMed ID: 9349299
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Baseline level and early suppression of serum HCV RNA for predicting sustained complete response to alpha-interferon therapy.
    Izopet J; Payen JL; Alric L; Sandres K; Charlet JP; Vinel JP; Duffaut M; Pascal JP; Puel J
    J Med Virol; 1998 Feb; 54(2):86-91. PubMed ID: 9496364
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Retreatment with interferon-alpha and ribavirin in primary interferon-alpha non-responders with chronic hepatitis C.
    Teuber G; Berg T; Hoffmann RM; Leifeld L; Lafrenz M; Spengler U; Pape GR; Hopf U; Zeuzem S
    Digestion; 2000; 61(2):90-7. PubMed ID: 10705172
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hepatitis C virus RNA load in relapsed patients: week two of treatment is the best time to predict the complete response.
    Halfon P; Khiri H; Tran A; Pénaranda G; Courcambeck J; Joly H; Ouzan D
    Eur J Gastroenterol Hepatol; 2003 Oct; 15(10):1067-71. PubMed ID: 14501613
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa.
    Zeuzem S; Lee JH; Franke A; Rüster B; Prümmer O; Herrmann G; Roth WK
    Hepatology; 1998 Apr; 27(4):1149-56. PubMed ID: 9537457
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Early hepatitis C virus-RNA responses predict interferon treatment outcomes in chronic hepatitis C. The Consensus Interferon Study Group.
    Lee WM; Reddy KR; Tong MJ; Black M; van Leeuwen DJ; Hollinger FB; Mullen KD; Pimstone N; Albert D; Gardner S
    Hepatology; 1998 Nov; 28(5):1411-5. PubMed ID: 9794929
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.